Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the voting results of its annual and special meeting of shareholders held on Sept. 22, 2026. According to the company, 46,452,598 common shares were represented at the meeting, representing 63.58% of outstanding shares as of the record date. Shareholders approved several key proposals, including the appointment of Zeifmans LLP as auditor, the setting of the board at eight directors, and the election of Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So as directors. Additionally, shareholders approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1. This legal name change follows the adoption of the Helus Pharma business name on Jan. 5 and reflects the company’s anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
For patients and healthcare providers, this rebranding may signal that Helus Pharma is moving closer to bringing its novel treatments to market. The company is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. These programs target large unmet needs in mental health, where existing therapies often fail to provide durable relief. Successful commercialization could expand treatment options for millions suffering from depression and anxiety.
From an industry perspective, the name change and board election could enhance Helus Pharma’s credibility as it transitions to a commercial-stage company. The new board brings together individuals with diverse expertise, which may help guide the company through regulatory milestones and market launch preparations. Investors may view the shareholder approval as a vote of confidence in the company’s strategic direction. The company operates in Canada, the United States, the United Kingdom and Ireland, positioning it to address mental health markets across multiple regions. For more information about Helus Pharma, visit www.helus.com. The full press release can be viewed at https://nnw.fm/H4DVg. The latest news and updates relating to HELP are available in the company’s newsroom at Helus Pharma.
This announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also offers corporate communications solutions and social media distribution to millions of followers. For full terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
